 CAMBRIDGE, Mass.--BUSINESS WIRE--- AVRO--AVROBIO, Inc. Nasdaq: AVRO, a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that updated clinical data from its ongoing, collaborator-sponsoredi Phase 12 clinical trial in cystinosis will be presented on Feb. 9, 2022, at the 18th Annual WORLDSymposiumTM in San Diego, Calif. Additionally, preclinical data from its Pompe disease and Hunter syndrome programs, as well as data on its 